A Multi-Cancer Early Detection (MCED) test is an emerging class of blood tests (often called “liquid biopsies”) designed to screen for signals from dozens of different types of cancer simultaneously from a single blood draw.
Unlike traditional cancer screenings that target one specific organ—such as a mammogram for breast cancer or a colonoscopy for colorectal cancer—MCED tests look for biological signals shed into the bloodstream by tumor cells throughout the body.
How MCED Tests Work
When cells (both normal and cancerous) die, they release fragments of DNA and other molecules into the blood stream, known as cell-free DNA (cfDNA).
1. Blood Draw: A healthcare provider collects a routine blood sample.
2. Genomic Analysis: Next-generation sequencing analyzes the cfDNA for specific chemical modifications (such as DNA methylation patterns) or mutations characteristic of cancer cells.
3. Cancer Signal Origin: Advanced machine learning algorithms look for the specific “fingerprint” of the DNA to identify not only whether a cancer signal is present, but also where in the body the signal likely originated (e.g., pancreas, liver, esophagus, ovary).
Current Status & Considerations
Complementary, Not a Replacement: Leading medical organizations emphasize that MCED tests are intended to supplement existing, recommended screenings (like colonoscopies, Pap smears, and mammograms), not replace them.
Detecting Hard-to-Find Cancers: A major potential benefit of MCED technology is detecting cancers that currently have no routine screening options—such as pancreatic, ovarian, esophageal, and stomach cancers—at earlier, more treatable stages.
Follow-up Needed: A “signal detected” result is not a definitive diagnosis. It indicates a high probability of cancer and guides doctors on where to run targeted diagnostic tests (like MRI, PET scan, or tissue biopsy) to confirm.
Availability: Tests like GRAIL’s Galleri are available in the U.S. under prescription (often out-of-pocket or through specific clinical trials), while large-scale clinical trials (including major studies by the NCI and NHS) continue to evaluate their impact on overall mortality.
Yes, you can request the GRAIL Galleri test online, but because it requires a prescription, the ordering process involves a physician’s approval.
How to Order Online
1. Request via Independent Telemedicine: You can initiate a request directly through GRAIL’s website (galleri.com) or affiliated digital health platforms (such as Everlywell).
2. Medical Review: An independent telemedicine doctor will review your medical history to determine if the test is appropriate for you.
3. Prescription Approval: If approved, the telemedicine physician will write the prescription and issue the lab order.
4. Blood Draw: Since the Galleri test requires blood to be drawn, you will either go to a partner laboratory (such as Quest Diagnostics) or arrange for a mobile phlebotomist to collect your sample.
5. Results: Test results are typically returned in about two weeks and are made available through your online portal or consulting physician.
Cost and Insurance Considerations
Price: The list price for the test is $949 (though self-pay discounts or promotions on Galleri.com may reduce it to around $799).
Insurance Coverage: Most commercial insurance plans do not currently cover the test, so it is primarily an out-of-pocket expense. However, you can often use pre-tax funds from a Flexible Spending Account (FSA) or Health Savings Account (HSA).
Key Requirements
The test is recommended primarily for adults with an elevated risk of cancer, such as those aged 50 or older.
It is not recommended for individuals currently undergoing active cancer treatment or those who are pregnant.